{"id":725121,"title":"Archived 34: Summary of NACI statement of March 11, 2022: Recommendations on the use of Medicago COVID-19 vaccine (Covifenz) - Canada.ca","sourceCode":"phac","sourceName":"Public Health Agency of Canada","language":"en","captureDate":"2026-03-09","captureTimestamp":"2026-03-09T18:44:26.889000+00:00","jobId":7,"originalUrl":"https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-medicago-covid-19-vaccine/summary-march-11-2022.html","snippet":"Archived 34: Summary of NACI statement of March 11, 2022: Recommendations on the use of Medicago COVID-19 vaccine (Covifenz) Notice to reader This is an archived version. Please refer to current COVID-19 vaccine pages: NACI statements and publications COVID-19 vaccine: Canadian…","rawSnapshotUrl":"/api/snapshots/raw/725121","browseUrl":"https://replay.healtharchive.ca/job-7/20260309184426/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-medicago-covid-19-vaccine/summary-march-11-2022.html#ha_snapshot=725121","mimeType":"text/html","statusCode":200,"captureBackend":"playwright_warc","captureFidelity":"fallback"}